![]() Unvaccinated or previously received any number of Original monovalent or bivalent mRNA vaccine doses: 1 dose of an updated (2023–2024 Formula) mRNA vaccine from either manufacturer (i.e., Moderna or Pfizer-BioNTech).Previously received all doses in the initial vaccination series with Original monovalent or bivalent mRNA vaccine: 1 homologous updated (2023–2024 Formula) mRNA vaccine dose.Previously received an incomplete series of Original monovalent or bivalent mRNA vaccine doses: Complete the vaccination series with 1 or 2 homologous updated (2023–2024 Formula) mRNA vaccine doses, depending on vaccine manufacturer and the number of previous vaccine doses.Unvaccinated: 2 or 3 homologous (i.e., from the same manufacturer) updated (2023–2024 Formula) mRNA vaccine doses, depending on vaccine manufacturer (i.e., Moderna, Pfizer-BioNTech).The recommended vaccine type and number of updated (2023–2024 Formula) COVID-19 vaccine doses are based on age and vaccination history. The COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised is detailed in Table 1. Vaccine doses should be administered by the intramuscular route. However, for COVID-19 vaccination there is an exception for children who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 years to 5 years during the 3-dose vaccination series (see Transitioning from a younger to older age group). In general, CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination and in accordance with the recommended intervals for that age group ( 1 ). See Appendix A for recommendations for people who received COVID-19 vaccine outside the United States. Vaccination schedules can be found in Table 1 for people who are not moderately or severely immunocompromised and in Table 2 for people who are moderately or severely immunocompromised. There is no preferential recommendation for the use of any one COVID-19 vaccine over another when more than one recommended and age-appropriate vaccine is available. CDC recommends that people stay up to date with COVID-19 vaccination. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months. ![]() COVID-19 Vaccine Product Information can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.ĬOVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. ![]() The Original monovalent and bivalent (Original and Omicron BA.4/BA.5) formulations should no longer be used.ĬOVID-19 vaccine-specific package inserts and FDA fact sheets and U.S. The 2023–2024 formulation for all COVID-19 vaccines licensed or authorized in the United States (Moderna, Novavax, and Pfizer-BioNTech) has been updated to a monovalent vaccine based on the Omicron XBB.1.5 sublineage of SARS-CoV-2.Novavax COVID-19 Vaccine, Adjuvanted (hereafter referred to as Novavax COVID-19 Vaccine) is authorized for people ages 12 years and older. ![]() These vaccines are hereafter referred to as updated (2023–2024 Formula) Pfizer-BioNTech COVID-19 Vaccine. Pfizer-BioNTech COVID-19 Vaccine (2023–2024 Formula) is authorized for children ages 6 months–11 years COMIRNATY is the licensed Pfizer-BioNTech product for people ages 12 years and older.These vaccines are hereafter referred to as updated (2023–2024 Formula) Moderna COVID-19 Vaccine. Moderna COVID-19 Vaccine (2023–2024 Formula) is authorized for children ages 6 months–11 years SPIKEVAX is the licensed Moderna product for people ages 12 years and older.Two types of COVID-19 vaccines are available for use in the United States: ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |